The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Cardiovascular adverse events following treatment with BTK inhibitors in CLL & MCL
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, comments on the occurrence of cardiovascular adverse events following treatment with BTK inhibitors (BTKi) in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), highlighting their impact on treatment decisions. Evidence from clinical trials has shown that second-generation agents including acalabrutinib may have a reduced rate of cardiovascular events compared to first-generation agents like ibrutinib. Prof. Danilov also notes that heart disease and other comorbidities are important considerations for the treatment of CLL and other B-cell malignancies. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Nurix: Consultancy, Research Funding; Takeda Oncology: Research Funding; Astra Zeneca: Consultancy, Research Funding; Bayer Oncology: Research Funding; Bristol-Meyers-Squibb: Consultancy, Research Funding; Cyclacel: Research Funding; MEI: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding; Genentech: Consultancy; Morphosys: Consultancy; Incyte: Consultancy; Beigene: Consultancy; GSK: Consultancy; Pharmacyclics: Consultancy.
